VRTX
Vertex Pharmaceuticals Incorporated
$437.71
+$3.19(+0.73%)
56
Overall
60
Value
45
Tech
63
Quality
Market Cap
$110.23B
Volume
244.01K
52W Range
$362.50 - $507.92
Target Price
$549.17
Order:
Income Statement
| Metric | Trend | Chart | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec | 2025 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $1.7B | $2.5B | $3.0B | $4.2B | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B | ||
| Total Revenue | $1.7B | $2.2B | $3.0B | $4.2B | $6.2B | $7.6B | $8.9B | $9.9B | $11.0B | $12.0B | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $206.8M | $275.1M | $409.5M | $547.8M | $736.3M | $904.2M | $1.1B | $1.3B | $1.5B | $1.7B | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $1.5B | $2.2B | $2.6B | $3.6B | $5.5B | $6.7B | $7.9B | $8.6B | $9.5B | $10.3B | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $1.5B | $1.8B | $2.0B | $2.4B | $2.6B | $3.9B | $3.6B | $4.8B | $9.7B | $5.8B | ||
| Research & Development | $1.0B | $1.3B | $1.4B | $1.8B | $1.8B | $3.1B | $2.7B | $3.7B | $8.3B | $4.0B | ||
| Research Expense | $1.0B | $1.3B | $1.4B | $1.8B | $1.8B | $3.1B | $2.5B | $3.2B | $3.6B | $3.9B | ||
| Selling, General & Administrative | $432.8M | $496.1M | $557.6M | $658.5M | $770.5M | $840.1M | $944.7M | $1.1B | $1.5B | $1.8B | ||
| Selling & Marketing Expenses | $432.8M | $496.1M | $557.6M | $658.5M | $770.5M | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-19.1M | $-19.2M | $-17.3M | $-136.2M | $-151.3M | $840.1M | $944.7M | $1.1B | $1.5B | $1.8B | ||
| Promotion & Advertising | $-31.4M | $-35.2M | $-43.5M | -- | -- | -- | -- | -- | -- | -- | ||
| Salaries & Wages | $-237.7M | $-293.2M | $-325.0M | $-360.5M | $-429.5M | $-82.9M | -- | -- | -- | -- | ||
| Depreciation & Amortization | $-60.8M | $-61.4M | $-72.4M | $-106.9M | $-109.5M | $125.6M | $148.3M | $167.8M | $160.4M | -- | ||
| Depreciation & Amortization | $-60.8M | $-61.4M | $-72.4M | $-106.9M | $-109.5M | $125.6M | -- | -- | -- | -- | ||
| Amortization | -- | -- | -- | $-49.8M | $-51.2M | $1.1B | $51.0M | $1.1B | $1.1B | -- | ||
| Other Operating Expenses | -- | $-3.8M | $-9.7M | $-14.4M | $-26.7M | $-42.0M | -- | -- | -- | -- | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $11.2M | $392.8M | $664.0M | $1.2B | $2.9B | $2.8B | $4.3B | $3.8B | $-232.9M | $4.2B | ||
| EBITDA | $-6.0M | $45.7M | $745.1M | $1.6B | $3.3B | $2.9B | $4.4B | $4.6B | $486.3M | $4.9B | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | -- | -- | $72.5M | $58.5M | $58.2M | $61.5M | $54.8M | $44.1M | $30.6M | $13.3M | ||
| Intinc | $-81.4M | $-57.5M | $-34.1M | -- | -- | -- | $144.6M | $614.7M | $598.1M | $490.9M | ||
| Net Non-Operating Interest Income/Expense | $-81.4M | $-57.5M | $-72.5M | $-58.5M | $50.2M | $-61.5M | $-89.8M | $-38.8M | $567.5M | $477.6M | ||
| Gain on Sale of Securities | -- | -- | $2.6M | $168.3M | $144.4M | $17.1M | -- | -- | -- | -- | ||
| Other Income/Expense | $-4.1M | $336.7M | $-8.6M | $-251.4M | $-305.7M | $-12.9M | $-222.8M | $-28.8M | $85.6M | $388.8M | ||
| Other Special Charges | $4.1M | $-81.4M | $37.6M | $255.9M | $318.8M | $9.8M | $-164.8M | $-22.8M | $-86.1M | $-7.7M | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | $1.3M | $14.2M | $-184.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Special Income Charges | $-1.3M | $-14.2M | $184.0K | -- | -- | -- | -- | $-11.8M | $-25.2M | -- | ||
| Other Impairment Of Capital Assets | -- | $255.3M | $29.0M | -- | -- | -- | -- | -- | -- | $379.0M | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-67.4M | $-15.7M | $672.7M | $1.5B | $3.2B | $2.8B | $4.3B | $4.4B | $279.1M | $4.7B | ||
| Pre-Tax Income | $-67.4M | $-15.7M | $600.2M | $1.4B | $3.1B | $2.7B | $4.2B | $4.4B | $248.5M | $4.6B | ||
| INCOME TAX | ||||||||||||
| Tax Provision | $16.7M | $-107.3M | $-1.5B | $218.1M | $405.2M | $388.3M | $910.4M | $760.2M | $784.1M | $690.0M | ||
| NET INCOME | ||||||||||||
| Net Income | $-112.1M | $263.5M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | $-535.6M | $4.0B | ||
| Net Income (Continuing Operations) | $-112.1M | $263.5M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | $-535.6M | $4.0B | ||
| Net Income (Discontinued Operations) | $-112.1M | $263.5M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | $-535.6M | $4.0B | ||
| Net Income (Common Stockholders) | $-112.1M | $263.5M | $2.1B | $1.2B | $2.7B | $2.3B | $3.3B | $3.6B | $-535.6M | $4.0B | ||
| Normalized Income | $-42.5M | $146.6M | $-857.8M | $1.1B | $2.5B | -- | -- | -- | -- | $5.0B | ||
| TOTALS | ||||||||||||
| Total Expenses | $1.7B | $2.1B | $2.4B | $3.0B | $3.3B | $4.8B | $4.7B | $6.1B | $11.3B | $7.4B | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $244.7M | $248.9M | $254.3M | $256.7M | $259.8M | $257.7M | $256.1M | $257.7M | $257.9M | $255.7M | ||
| Average Shares Outstanding (Diluted) | $244.7M | $253.2M | $259.2M | $260.7M | $263.4M | $259.9M | $259.1M | $260.5M | $257.9M | $258.0M | ||
| Shares Outstanding | $248.4M | $253.9M | $255.7M | $259.3M | $260.0M | $254.6M | $257.1M | $258.3M | $256.8M | $253.8M | ||
| Basic EPS | $0.13 | $1.06 | $8.24 | $4.58 | $10.44 | $9.09 | $12.97 | $14.05 | $-2.08 | $15.46 | ||
| Basic EPS (Continuing Operations) | $-0.46 | -- | -- | -- | -- | $9.09 | $12.97 | $14.05 | $-2.08 | $15.46 | ||
| Diluted EPS | $0.13 | $1.04 | $8.09 | $4.51 | $10.29 | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 | ||
| Diluted EPS (Continuing Operations) | $-0.46 | -- | -- | -- | -- | $9.01 | $12.82 | $13.89 | $-2.08 | $15.32 | ||
| OTHER METRICS | ||||||||||||
| Development Expense | -- | -- | -- | -- | -- | -- | $115.5M | $527.1M | $4.6B | $133.0M | ||
| Minority Interests | $-28.0M | $171.8M | $9.8M | -- | -- | -- | -- | -- | -- | -- | ||
| Net Operating Interest Income Expense | -- | -- | -- | -- | $-58.2M | -- | -- | -- | -- | -- | ||
| Other Gand A | $-19.1M | $-19.2M | $-17.3M | $-136.2M | $-151.3M | $840.1M | $944.7M | $1.1B | $1.5B | $1.8B | ||
| Rent And Landing Fees | $-19.1M | $-19.2M | $-17.3M | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $432.8M | $496.1M | $557.6M | $658.5M | $770.5M | -- | -- | -- | -- | -- | ||
| Restruct | $1.3M | $14.2M | $-184.0K | -- | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VRTX | $437.71 | +0.7% | 244.01K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Vertex Pharmaceuticals Incorporated Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW